MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time.
A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email This email address is being protected from spambots. You need JavaScript enabled to view it..
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox,
Vice President, Communications,
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
Chris Calabrese, This email address is being protected from spambots. You need JavaScript enabled to view it.
Kevin Gardner, This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.97 |
| Daily Change: | -0.08 -3.90 |
| Daily Volume: | 1,152,518 |
| Market Cap: | US$167.430M |
October 09, 2025 August 19, 2025 August 12, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
